Can I Take Saw Palmetto with Repatha (Evolocumab)?

What Repatha (Evolocumab) Actually Does

Repatha is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that tags LDL receptors on hepatocytes for degradation. By blocking PCSK9, evolocumab keeps more LDL receptors on the liver surface, which pulls LDL-C out of the bloodstream.

Clinical efficacy data

In the FOURIER trial (N=27,564 patients with established ASCVD on statin therapy), evolocumab 140 mg every 2 weeks reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite cardiovascular endpoint (MI, stroke, or CV death) by 15% versus placebo over a median follow-up of 2.2 years (P<0.001) [1].

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with very high-risk ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended." [2]

How evolocumab is broken down

This is the single most important pharmacokinetic fact for evaluating any supplement interaction. Evolocumab is a large protein (molecular weight ~144 kDa). The body does not metabolize it through the cytochrome P450 enzyme system. It is broken down by the same proteolytic pathways that catabolize endogenous immunoglobulins, primarily via PCSK9-mediated target-mediated drug disposition and general IgG catabolism [3].

That means supplements that inhibit or induce CYP3A4, CYP2C9, or CYP2D6 cannot alter evolocumab's plasma concentration, half-life, or efficacy. Grapefruit juice, St. John's Wort, and similar CYP-active supplements are a real concern with statins like atorvastatin. They are not a concern with evolocumab.

What Saw Palmetto Does in the Body

Saw palmetto (Serenoa repens) is an extract from the fruit of a small fan palm native to the southeastern United States. It is used most often by men for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), and to a lesser extent for hair loss and hormonal support.

Mechanism of action

Saw palmetto's primary proposed mechanism is inhibition of 5-alpha reductase (5-AR), the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT). Some in-vitro studies also suggest weak alpha-1 adrenergic blockade and anti-inflammatory effects via cyclooxygenase inhibition [4].

The 5-AR inhibition pathway has no identified connection to PCSK9 biology, hepatic LDL receptor expression, or the lipid metabolism cascade.

Antiplatelet activity

Saw palmetto contains phytosterols and fatty acids that may inhibit thromboxane B2 production and reduce platelet aggregation in vitro [5]. This is a pharmacodynamic effect, meaning it influences a physiological process rather than changing a drug's concentration.

A 2012 systematic review published in the Journal of Urology (Tacklind et al., N=5,666 participants across 32 trials) found no statistically significant increase in bleeding adverse events compared to placebo at standard doses of 160 mg twice daily [6]. The bleeding signal exists at the case-report level, particularly in perioperative settings, but no randomized controlled trial has quantified its magnitude.

CYP enzyme profile

In cell-based assays, saw palmetto extract shows weak inhibitory activity toward CYP3A4 and CYP2C9 [7]. As established above, these enzymes do not process evolocumab. So even the mild CYP activity of saw palmetto carries zero practical relevance for Repatha blood levels.

Interaction Analysis: Evolocumab Plus Saw Palmetto

The bottom line is straightforward. There is no pharmacokinetic interaction between saw palmetto and evolocumab because the two molecules never compete for the same metabolic machinery.

Pharmacokinetic dimension (no interaction found)

Evolocumab's proteolytic catabolism is entirely separate from the hepatic and intestinal CYP system that saw palmetto weakly modulates. Saw palmetto cannot speed up or slow down evolocumab clearance. It cannot reduce peak drug concentration. A dose-separation window, like the 2-hour separation often recommended between statins and bile-acid sequestrants, is not necessary here.

Pharmacodynamic dimension (theoretical, low magnitude)

The interaction concern that does exist is pharmacodynamic: both saw palmetto and evolocumab may, through entirely different routes, modestly affect bleeding risk in a high-cardiovascular-risk patient.

Evolocumab itself is not an anticoagulant. The FOURIER trial did not show a statistically significant increase in major bleeding events with evolocumab compared to placebo [1]. Many patients on Repatha, however, are also prescribed aspirin 81 mg daily, P2Y12 inhibitors such as clopidogrel or ticagrelor, or anticoagulants such as rivaroxaban.

If a patient takes all of the following: aspirin 81 mg, ticagrelor 90 mg twice daily, evolocumab 140 mg every 2 weeks, and saw palmetto 160 mg twice daily, the saw palmetto's antiplatelet activity is pharmacodynamically additive with the antiplatelet agents, not with evolocumab directly. The prescriber needs to know about the supplement so the whole picture of antiplatelet burden can be assessed.

Effect on LDL-C (no interference expected)

Saw palmetto does not influence LDL-C. It does not affect hepatic cholesterol synthesis, LDL receptor expression, or PCSK9 protein levels in published human data. Taking saw palmetto will not blunt the 59% LDL-C reduction that evolocumab produces [1].

The HealthRX clinical team uses a three-question screening framework when evaluating any supplement alongside a PCSK9 inhibitor:

1. Does the supplement inhibit or induce CYP3A4, CYP2C9, or another enzyme that metabolizes the drug? (For evolocumab: irrelevant, because no CYP pathway is involved.)
2. Does the supplement affect the same physiological target the drug acts on, either additively or antagonistically? (For saw palmetto plus evolocumab: no shared target.)
3. Does the supplement add pharmacodynamic burden to any co-prescribed drug (antiplatelet, anticoagulant, antihypertensive)? (For saw palmetto: possibly yes, if the patient is also on antiplatelet therapy.)

Only question three generates a clinical action item here.

Who Should Be Most Cautious

Patients on dual antiplatelet therapy

Post-ACS patients who take both aspirin and a P2Y12 inhibitor (dual antiplatelet therapy, or DAPT) carry meaningful baseline bleeding risk. The PLATO trial showed that ticagrelor plus aspirin reduced MACE by 16% versus clopidogrel plus aspirin in ACS patients (N=18,624), but bleeding rates were also higher [8]. Adding a supplement with any antiplatelet activity to DAPT warrants disclosure to the prescribing cardiologist, even if the interaction magnitude is small.

Patients on anticoagulants

Some patients with ASCVD and concurrent atrial fibrillation take a direct oral anticoagulant (DOAC) such as rivaroxaban or apixaban alongside their Repatha. The COMPASS trial demonstrated that rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily reduced MACE in stable ASCVD by 24% versus aspirin alone (N=27,395), while raising major bleeding by 70% relative to aspirin monotherapy [9]. Patients in this category should discuss saw palmetto use explicitly with their anticoagulation manager.

Patients scheduled for procedures

The Society for Cardiovascular Angiography and Interventions (SCAI) generally recommends that herbal supplements with antiplatelet properties be discontinued 5 to 7 days before elective invasive procedures [10]. Evolocumab itself does not need to be paused perioperatively (its half-life is approximately 11 to 17 days and missing one injection does not acutely reverse LDL-C benefit), but saw palmetto should be on the pre-procedure medication review list.

Men using saw palmetto for PSA management

5-AR inhibitors, including finasteride and dutasteride, can lower PSA by up to 50%, which may mask prostate cancer screening signals. Saw palmetto's 5-AR inhibitory effect is far weaker than pharmaceutical 5-AR inhibitors, and a 2011 Cochrane review (Tacklind et al.) found no statistically significant effect of saw palmetto on PSA compared to placebo [11]. This PSA consideration is independent of Repatha therapy but relevant to any patient on both agents.

What the Guidelines Say

The 2022 ACC/AHA Guideline on Cholesterol Management does not mention saw palmetto in the context of PCSK9 inhibitor therapy [2]. The American Heart Association's 2023 Scientific Statement on Dietary Supplements and Cardiovascular Health does not list saw palmetto as an agent that interferes with PCSK9 inhibitor pharmacology [12].

The Natural Medicines Comprehensive Database rates the saw palmetto plus anticoagulant/antiplatelet combination as a "moderate" interaction based on theoretical pharmacodynamic additivity, not on clinical trial evidence of harm.

The FDA label for Repatha does not list any herbal supplement, including saw palmetto, as a contraindication or warning [13].

Practical Steps for Patients Currently Taking Both

Taking saw palmetto and evolocumab together is not contraindicated. The steps below apply to the pharmacodynamic context outlined above.

Step 1: Disclose at your next Repatha refill visit

Tell your prescriber and pharmacist you are taking saw palmetto, the dose (most commonly 160 mg twice daily or 320 mg once daily), and how long you have been using it. This disclosure should be documented in your medication list. Supplements are routinely omitted from pharmacy records, which creates gaps in drug-interaction screening.

Step 2: List all antiplatelet and anticoagulant agents

Ask your care team to do a complete antiplatelet burden review, covering aspirin, NSAIDs taken regularly, P2Y12 inhibitors, DOACs, and saw palmetto together. The goal is to assess the combined pharmacodynamic effect, not to single out any one agent.

Step 3: No dose-separation window needed

You do not need to separate saw palmetto doses from your evolocumab injection by any particular time window. Dose separation matters when two agents compete for the same transporter or enzyme. That competition does not exist here.

Step 4: Report unusual bruising or bleeding

If you notice bruising that takes longer than usual to resolve, prolonged bleeding from minor cuts, or unexpected nosebleeds, report these to your prescriber. They suggest the pharmacodynamic burden of all your antiplatelet-active agents may be clinically significant for you as an individual.

Step 5: Confirm before any surgery or procedure

Tell the surgical team and anesthesiologist about saw palmetto during the pre-procedure assessment, regardless of whether you consider it a "medication." Many surgical teams request discontinuation 7 days before elective procedures involving regional anesthesia or high bleeding risk.

Does Saw Palmetto Affect Cholesterol or PCSK9 Levels?

This question comes up because some plants contain phytosterols that can modestly lower LDL-C. Saw palmetto fruit contains beta-sitosterol, campesterol, and stigmasterol, the same class of compounds found in prescription plant-sterol supplements.

A 2020 meta-analysis of plant sterol supplements across 41 RCTs (N=2,284) showed that 2 g per day of plant sterols reduced LDL-C by approximately 9% [14]. The typical saw palmetto supplement, however, is standardized to its liposterolic fraction, not to a specific plant sterol content. The doses of free phytosterols in a 160 mg saw palmetto capsule are far below the 2 g per day threshold studied in plant sterol trials.

No published human trial has demonstrated that saw palmetto supplementation at doses of 160 to 320 mg daily significantly alters serum LDL-C, HDL-C, or measured PCSK9 protein levels.

Evolocumab Pharmacokinetics: A Closer Look

Understanding why saw palmetto cannot pharmacokinetically interfere with Repatha requires a brief review of how monoclonal antibodies are handled by the body.

Absorption and distribution

Evolocumab is injected subcutaneously. Peak plasma concentration (Tmax) occurs at a median of 3 to 4 days after injection. Absolute bioavailability following subcutaneous administration is approximately 72% [3]. Oral supplements cannot interfere with subcutaneous absorption because they are absorbed from the gut, not the injection site.

Catabolism pathway

After binding PCSK9, the evolocumab-PCSK9 complex undergoes endosomal degradation via target-mediated drug disposition. Free antibody is catabolized through the FcRn salvage pathway, the same system that governs the half-life of native IgG antibodies. Neither the FcRn receptor, the endosomal protease pathway, nor PCSK9 itself is modulated by saw palmetto or its components.

Half-life and missed doses

The mean terminal half-life of evolocumab is approximately 11 to 17 days, depending on dose and body weight. If a patient misses one biweekly 140 mg injection due to an adverse event, LDL-C begins to drift upward within 1 to 2 weeks, but does not return to baseline for several weeks. Saw palmetto does not accelerate this drift.

A Note on Supplement Quality and Labeling

Saw palmetto products are not FDA-approved drugs. They are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require pre-market efficacy or safety review. A 2011 ConsumerLab analysis found that 10 of 27 commercially available saw palmetto products failed to meet label claims for standardized fatty acid content, the component believed responsible for 5-AR inhibition.

If you use saw palmetto, choose a product that is third-party certified by NSF International, USP, or ConsumerLab to reduce the risk of adulteration or mislabeling. Poorly standardized products add an extra layer of unpredictability to any pharmacodynamic risk assessment.

The FDA maintains a database of supplement safety alerts and recalls [15]. Checking it periodically is a reasonable practice for anyone on high-stakes cardiovascular therapy like evolocumab.